Drug-resistant tuberculosis - What do we do now?

被引:33
|
作者
Telenti, A [1 ]
Iseman, M
机构
[1] CHU Vaudois, Div Infect Dis, CH-1011 Lausanne, Switzerland
[2] CHU Vaudois, Inst Microbiol, CH-1011 Lausanne, Switzerland
[3] Natl Jewish Med & Res Ctr, Denver, CO USA
关键词
D O I
10.2165/00003495-200059020-00002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Drug-resistant tuberculosis (TB) represents a threat to TB control programmes. Erratic and inappropriate use of currently available medications, HIV-TB coinfection, and concern about transmission of drug-resistant strains in the general population all contribute to a worrying picture. What do we do now? In the last few years, there has been considerable progress in the understanding of mechanisms of action and resistance to antituberculosis agents, and in establishing the value of directly observed therapy in preventing treatment failure. However, a limited effort has been devoted to the development of new active compounds or of rapid diagnostic tests, and their relevance to global tuberculosis control has been questioned.
引用
收藏
页码:171 / 179
页数:9
相关论文
共 50 条
  • [1] Drug-Resistant TuberculosisWhat Do We Do Now?
    Amalio Telenti
    Michael Iseman
    [J]. Drugs, 2000, 59 : 171 - 179
  • [2] Direct Observation (DO) for Drug-Resistant Tuberculosis: Do We Really DO?
    Benbaba, Stella
    Isaakidis, Petros
    Das, Mrinalini
    Jadhav, Sonakshi
    Reid, Tony
    Furin, Jennifer
    [J]. PLOS ONE, 2015, 10 (12):
  • [3] Do we need a new Fleming epoque: The nightmare of drug-resistant tuberculosis
    Sotgiu, Giovanni
    Centis, Rosella
    D'Ambrosio, Lia
    Tadolini, Marina
    Castiglia, Paolo
    Migliori, Giovanni Battista
    [J]. INTERNATIONAL JOURNAL OF MYCOBACTERIOLOGY, 2013, 2 (03) : 123 - 125
  • [4] WHAT DO WE DO NOW
    SCHRODER, JL
    [J]. MINING CONGRESS JOURNAL, 1981, 67 (01): : 35 - 37
  • [5] WHAT DO WE DO NOW
    BARNES, DG
    [J]. ENVIRONMENTAL TOXICOLOGY AND CHEMISTRY, 1992, 11 (06) : 729 - 731
  • [6] Now What Do We Do?
    Treadwell, Terry
    [J]. WOUNDS-A COMPENDIUM OF CLINICAL RESEARCH AND PRACTICE, 2013, 25 (05): : A6 - A7
  • [7] What do we do now?
    Couldwell, C.
    [J]. Communications International (London), 2001, 28 (09): : 24 - 27
  • [8] What Do We Do Now?
    Rokach, Joshua Z.
    [J]. Electricity Journal, 2009, 22 (07): : 87 - 88
  • [9] Drug-Resistant Tuberculosis in Europe What Are We Waiting For?
    Monedero-Recuero, Ignacio
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 198 (03) : 302 - 304
  • [10] Extensively Drug-Resistant Tuberculosis (XDR TB) in Pakistan: Where do we stand
    Hassan, Afreenish
    [J]. PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2013, 7 (01): : 2 - 2